ARS Pharmaceuticals (SPRY) News
NASDAQ: SPRYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
2.96-0.40 (-11.90%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SPRY news summary
We found 4 recent headlines mentioning ARS Pharmaceuticals (SPRY): 0 in the past week and 4 in the past 30 days, most often from Nasdaq, GlobeNewswire. SPRY is making an outsized move today, down 11.90% at $2.96, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "ARS Pharma (SPRY) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest ARS Pharmaceuticals headlines
- ARS Pharma (SPRY) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- ARS Pharmaceuticals Reports Third Quarter 2026 Revenue of $37.7 millionARS Pharmaceuticals, Inc. reported its financial results for the third quarter ended September 30, 2026. Total revenue for the quarter was $37.7 million, which included $33.4 million in U.S. net…Nasdaq
- ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial ResultsTotal Q3 revenue of $37.7 million, including $33.4 million in U.S. net product revenue for neffy ®GlobeNewswire
- ARS Pharma to Report Third Quarter 2026 Financial ResultsSAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better…GlobeNewswire